BHC Q4 2025 Earnings Call Summary

Bausch Health (BHC) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

Q4 Revenue: $2.796 billion, up 9% year-over-year.
Adjusted EBITDA: $1.52 billion, a 13% increase from Q4 2024.
Adjusted Operating Cash Flow: $515 million.
Bausch Health (excluding Bausch + Lomb):
- Q4 Revenue: $1.391 billion, up 9% year-over-year.
- Adjusted EBITDA: $773 million, a 9% increase.
- Adjusted Operating Cash Flow: $362 million, down $205 million year-over-year due to cash interest payment timing.
Full Year 2025 Performance:
- Revenue growth of 7% and adjusted EBITDA growth of 10%, exceeding guidance.
- Salix and Solta segments reported double-digit growth of 11% and 18%, respectively.

2. Strategic Updates and Business Highlights:

Acquisition: On December 1, 2025, Bausch Health acquired Shibo, enhancing its aesthetics distribution in China.
Debt Management: Reduced net debt by approximately $320 million in Q4 and improved debt maturity profile by $1.7 billion through a debt exchange.
Salix Segment: Continued strong performance with resilient demand and effective promotional strategies.
Solta Segment: Despite a slight revenue decline, the acquisition of Shibo is expected to enhance growth in the aesthetics market.
International Segment: Mixed results with strong growth in EMEA and LatAm, but a contraction in Canada due to increased generic competition.

3. Forward Guidance and Outlook:

2026 Guidance:
- Expected revenues between $5.25 billion and $5.4 billion (3% increase year-over-year).
- Adjusted EBITDA forecasted between $2.875 billion and $2.950 billion (4% increase year-over-year).
- Adjusted operating cash flow expected to be between $1.2 billion and $1.275 billion.
Anticipated stronger growth in the first half of 2026 due to temporary benefits recorded in the latter half of 2025.

4. Bad News, Challenges, or Points of Concern:

RED-C Trial Results: Phase III trials did not meet primary endpoints, leading to a reassessment of development opportunities.
Xifaxan Exclusivity Risks: Potential for generic competition starting January 1, 2028, raises concerns about future revenue declines.
Operating Cash Flow Decline: Significant drop in adjusted operating cash flow in Q4 compared to the previous year, primarily due to timing of interest payments.
Market Pressures: Increased competition in the Canadian market, particularly for Wellbutrin, which faced generic competition.

5. Notable Q&A Insights:

Business Development Focus: The company is actively pursuing business development opportunities, leveraging its improved capital structure.
Xifaxan Sales Strategy: Management is focused on maximizing current sales before the expected decline due to generic competition.
Bausch + Lomb Separation: The company is considering selling its equity stake in Bausch + Lomb rather than spinning off the business, with a focus on maximizing shareholder value.
Debt Repayment Strategy: Management remains committed to debt repayment while also investing in business growth and product development.

Overall, Bausch Health demonstrated solid financial performance in 2025, with strategic acquisitions and improved debt management positioning the company for continued growth. However, challenges such as the disappointing RED-C trial results and impending generic competition for Xifaxan present significant risks to future performance.

BHC — Bausch Health Companies Inc.